How does clofarabine actually work inside leukemia cells?
Clofarabine is a nucleoside metabolic inhibitor that gets converted inside cancer cells into an active form that blocks DNA replication, stopping leukemia cells from copying themselves; 2023 meta-analysis showed 40–60% complete remission rates in relapsed/refractory acute lymphoblastic leukemia [1].
Clofarabine enters leukemia cells and is phosphorylated (activated) by an enzyme called deoxycytidine kinase into a triphosphate form that mimics natural DNA building blocks. Once activated, it gets incorporated into the cancer cell's DNA chain, causing chain termination and cell death. This mechanism is especially potent in rapidly dividing leukemia cells, which have high demand for DNA synthesis [1][9].
Think of clofarabine as a counterfeit DNA building block that cancer cells mistake for the real thing. When the cell tries to copy its DNA, it accidentally uses clofarabine instead of the genuine nucleoside, and the chain breaks. Normal cells are less vulnerable because they divide more slowly and have better DNA repair mechanisms than leukemia blasts [9].
The drug's effectiveness depends on the leukemia cell's sensitivity to nucleoside inhibitors and the patient's kidney and liver function, which clear the drug's metabolites. Pediatric patients often tolerate clofarabine better than older adults because their organs are more robust, but all patients require baseline kidney and liver labs before starting treatment [5][8].
Ask your oncologist: 'Will you check my kidney and liver function before we start, and how often will you repeat those labs during treatment?' This ensures the drug is being cleared safely and doses can be adjusted if needed.